Investigational drug for advanced bile duct or gallbladder cancer
Part of Cancer, Digestive system clinical trials.
This study tests an investigational drug called Benmelstobart (an immunotherapy) for people with advanced bile duct or gallbladder cancer that hasn't been treated yet. The goal is to see if the drug can shrink or control the tumor and to check its safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have gallbladder or bile duct cancer that cannot be removed with surgery and has not been treated yet.
- You can perform daily activities with little help (ECOG 0 or 1) and are expected to live at least 3 months.
- Your blood counts, liver and kidney function need to be within a certain range (your doctor will check this).
- You must not have other serious cancers, uncontrolled heart disease, or an active autoimmune disease.
- You must agree to use effective birth control during the study and for 6 months after.
- You need to provide a tissue sample for testing (a recent biopsy is preferred).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called envafolimab for people with advanced bile duct or gallbladder cancer. The goal is to see if it can help shrink tumors or slow the disease.
This study tests adding the immunotherapy adebrelimab to standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for advanced biliary tract cancer that can't be removed by surgery. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial tests a combination of three drugs for bile duct cancer that cannot be removed by surgery: sintilimab (an immunotherapy that helps your immune system fight cancer), bevacizumab (a drug that blocks blood vessel growth to tumors), and a standard chemotherapy called AG (gemcitabine and capecitabine). The goal is to see if this combination can help shrink or control the cancer as a first treatment option.
This study tests a combination of three drugs (gemcitabine, cisplatin, nab-paclitaxel) plus an immunotherapy (tislelizumab) for people with advanced biliary tract cancer who haven't had treatment yet. The goal is to see if this cocktail shrinks tumors better than standard care.
This trial is testing a combination of four drugs (gemcitabine, cisplatin, nab-paclitaxel, and durvalumab) for people with gallbladder cancer that has spread or cannot be removed by surgery. The goal is to see if this drug combination helps shrink or control the cancer.
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
Hear when a new Biliary Tract Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.